ALAVATTAM, Sreedhara,AMLER, Lukas C.,DE TOLEDO PELIZON, Christina H.,BENYUNES, Mark C.,CLARK, Emma L.,KWONG GLOVER, Zephania W.,MITCHELL, Lada,RATNAYAKE, Jayantha,ROSS, Graham A.,WALKER, Ru-Amir
申请号：
AU2018203970
公开号：
AU2018203970A1
申请日:
2018.06.05
申请国别(地区):
AU
年份:
2018
代理人:
摘要：
#$%^&*AU2018203970A120180621.pdf#####ABSTRACT The present application describes uses for and articles of manufacture including Pertuzumab, a first-in-class HER2 dimerization inhibitor. In particular, the application describes methods for extending progression free survival in a HER2-positive breast cancer patient population； combining two HER2 antibodies to treat HER2-positive cancer without increasing cardiac toxicity； treating early-stage HER2-positive breast cancer； treating HER2-positive cancer by co-administering a mixture of Pertuzumab and Trastuzumab from the same intravenous bag； treating HER2-positive metastatic gastric cancer； treating HER2-positive breast cancer with Pertuzumab, Trastuzumab and Vinorelbine； treating HER2-positive breast cancer with Pertuzumab, Trastuzumab and aromatase inhibitor； and treating low HER3 ovarian, primary peritoneal, or fallopian tube cancer. It also describes an article of manufacture comprising a vial with Pertuzumab therein and a package insert providing safety and/or efficacy data thereon； a method of making the article of manufacture； and a method of ensuring safe and effective use of Pertuzumab related thereto. In addition the application describes an intravenous (IV) bag containing a stable mixture of Pertuzumab and Trastuzumab suitable for administration to a cancer patient. 10341685_1 (GHMatters) P96260.AU.2
